Feb. 20, 2013
Immunotech Laboratories, Inc.
(PINKSHEETS: IMMB) Today
announced the following updates for the International Clinical Trials of the company's patented AIDS-HIV "IPF" Medicine(s).
Immunotech Founder and President
today announced the progress with the project IPF-ITV-1 in the European Union. Mr. Zhabilov stated: "We have negotiated with two of the biggest hospitals in
(thus, European Union) to carry our clinical trials of IPF-ITV-1 and ITV-2 as follows:
At the Infectious Disease Hospital,
, with Hospital Director Prof. Cherveniakova we will carry out clinical trials of ITV-1 with 50 patients infected with HIV-AIDS in its most advanced stage.
At the Military Hospital,
, with Hospital Director Prof. General
we will carry out clinical trials of ITV-2 with 50 patients ill with chronic hepatitis in its most advanced stage." The clinical trials will be conducted parallel with protease inhibitor.
Mr. Zhabilov further stated: "We believe that in both cases, the results will be very good, because in
until this point, we have already applied the experimental labeled "IPF" Medicine with HIV infected volunteers and the outcomes to date have been extremely successful."
Immunotech recently completed negotiations in the Republic of
who agreed to carry out clinical trials of IPF-ITV-3 with 50 patients ill with HCV using the "IPF" labeled Experimental Drug Medicines.
The clinical trials in
Referred to as, EU)
are scheduled to begin in
and end in
, which will give Immunotech, the rights to receive approval for huge applications of the "IPF" Medicines. In this respect, Immunotech has had a series of conversations with Mr.
, the Deputy General Director from Sopharma Bulgaria, and the parties have reached agreement for the signing of a contract between Immunotech Laboratories BG and Sopharma for joint production of IPF-ITV.
is a leading pharmaceutical company in the European Union.
RELEVANT ARTICLES & LINKS FOR AIDS-HIV MEDICINES
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids.